<DOC>
	<DOC>NCT00692172</DOC>
	<brief_summary>An extension study to evaluate safety and tolerability of up to 3 additional courses of IM alefacept in patients with chronic plaque psoriasis who have been previously treated with 1 or 2 courses of IM alefacept.</brief_summary>
	<brief_title>Open-label Study to Evaluate Safety of Multiple Courses of IM Alefacept During Treatment of Chronic Plaque Psoriasis</brief_title>
	<detailed_description />
	<mesh_term>Psoriasis</mesh_term>
	<mesh_term>Alefacept</mesh_term>
	<criteria>Must have received at least 8 injections in the C99717 study and completed the final followup visit OR, Must have completed the C99712 study and been in C99717 interim visits at the time dosing in the C99717 study was closed. A subject who completed C99712 but did not participate in any part of C99717, including interim visits, must have prior sponsor approval before admission into C728 Nursing mothers, pregnant women, and women planning to become pregnant while on study are to be excluded. Female patients who are not postmenopausal for at least 1 year, surgically sterile, or willing to practice effective contraception during the study Clinically significant abnormal hematology values or history of an immunosuppressive disorder Serious local infection or systemic infection within 3 months prior to the first dose of alefacept A significant change in the subject's medical history from their previous alefacept study Any subject who initiated alternative systemic therapy, phototherapy, or disallowed therapy prior to visit 8 in study C99712 or C99717 Current enrollment in any investigational study in which the subject is receiving any type of drug, biologic, or nondrug therapy (participation in registrytype studies is allowed)</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2014</verification_date>
	<keyword>psoriasis</keyword>
	<keyword>alefacept</keyword>
	<keyword>intramuscular</keyword>
</DOC>